Brokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.40

Posted by Francis Steltz on Aug 21st, 2026

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have been given an average rating of “Moderate Buy” by the seven analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $5.50.

A number of research analysts recently issued reports on EDIT shares. Weiss Ratings upgraded Editas Medicine from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. TD Cowen restated a “buy” rating on shares of Editas Medicine in a research note on Wednesday, May 27th. Wall Street Zen raised Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Chardan Capital raised their price target on shares of Editas Medicine from $3.50 to $4.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Editas Medicine in a research note on Tuesday. They set a “buy” rating and a $6.00 price target for the company.

Read Our Latest Stock Report on EDIT

Editas Medicine Trading Down 9.5%

Shares of NASDAQ EDIT opened at $2.94 on Friday. The firm has a market cap of $451.53 million, a PE ratio of -3.92 and a beta of 2.14. Editas Medicine has a 1-year low of $1.66 and a 1-year high of $4.54. The company has a fifty day moving average price of $2.92 and a 200 day moving average price of $2.70.

Editas Medicine (NASDAQ:EDIT – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.12. The firm had revenue of $11.89 million during the quarter, compared to analysts’ expectations of $2.85 million. Editas Medicine had a negative return on equity of 196.63% and a negative net margin of 157.32%. Equities research analysts forecast that Editas Medicine will post -0.85 EPS for the current year.

Insider Buying and Selling

In related news, CEO Gilmore Neil O’neill sold 15,380 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $2.70, for a total transaction of $41,526.00. Following the completion of the transaction, the chief executive officer owned 248,313 shares in the company, valued at approximately $670,445.10. This represents a 5.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 21,503 shares of company stock worth $57,910 in the last ninety days. Corporate insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Editas Medicine

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new position in shares of Editas Medicine in the 2nd quarter valued at about $31,000. Victory Capital Management Inc. acquired a new stake in shares of Editas Medicine in the third quarter valued at about $36,000. Pallas Capital Advisors LLC bought a new stake in Editas Medicine during the second quarter worth about $38,000. Captrust Financial Advisors bought a new stake in Editas Medicine during the second quarter worth about $26,000. Finally, Sei Investments Co. bought a new stake in Editas Medicine during the third quarter worth about $46,000. 71.90% of the stock is owned by institutional investors.

Editas Medicine Company Profile

(Get Free Report)

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.